Related Experiment Video
Updated: Jun 24, 2026
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Long-term augmentation therapy with alpha-1 antitrypsin in an MZ-AAT severe persistent asthma
1Department of Internal Medicine, Unit of Respiratory Diseases, Valle del Nalón Hospital, 33920 Polígono de Riaño s/n, Langreo, Principado de Asturias, Spain. ignacio.blanco@sespa.princast.es
Summary
Alpha1-antitrypsin (AAT) deficiency in an asthma patient improved significantly with AAT replacement therapy, halting lung decline and reducing hospitalizations. This case suggests AAT therapy may benefit asthma patients with protease-antiprotease imbalance.
Area of Science:
- Pulmonology
- Genetics
- Pharmacology
Background:
- Severe bronchial asthma and Alpha1-antitrypsin (AAT) deficiency (MZ phenotype) severely limited a young female's physical capacity.
- Standard antiasthmatic treatment and chronic corticosteroid use failed to prevent health decline and caused adverse effects like reduced bone density and muscle mass.
Observation:
- A clinical trial proposed intravenous AAT replacement therapy, despite it not being approved for MZ phenotypes.
- The patient's doctors initiated this therapy under a Spanish Ministry of Health-approved trial.
Findings:
- AAT replacement therapy rapidly halted the decline in lung function.
- Hospital admissions decreased dramatically, and oral prednisone administration was eliminated.
- Corticosteroid-related adverse effects were reversed, significantly improving the patient's quality of life.
Implications:
- This case supports the hypothesis that bronchial asthma may involve protease-antiprotease imbalance.
- AAT replacement therapy, though not indicated for MZ asthma, shows potential benefits.
- Further research into AAT's role in asthma pathogenesis and treatment is warranted.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:30Asthma-IV: Diagnostic and Management
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:23Chronic Obstructive Pulmonary Disease II: Emphysema
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...